HomeAbout

TL;DR CNBC


Moderna says new Covid vaccine was effective against Eris variant in early trial - TL;DR CNBC

Moderna says new Covid vaccine was effective against Eris variant in early trial

Publishing timestamp: 2023-08-17 19:50:14


Summary

Moderna's new Covid vaccine has shown a robust immune response against the dominant Eris variant and another rapidly spreading strain of the virus in clinical trials. The updated shot is designed to target the omicron subvariant XBB.1.5. The results suggest that the vaccine may still be effective against newer variants of the virus. Pfizer also announced that their updated Covid shot effectively neutralized XBB.1.5 and Eris in recent trials on mice. Both Moderna's and Pfizer's new vaccines are expected to roll out within weeks pending FDA approval.


Sentiment: POSITIVE

Tickers: NVAXPFEMRNA

Keywords: business newsbiotech and pharmaceuticalsbusinessbiotechnologycovid-19pfizer inccoronavirusbreaking newspharmaceuticalsnovavax incvaccinationssciencemoderna inchealth care industry

Source: https://www.cnbc.com/2023/08/17/moderna-covid-vaccine-effective-against-eris-fornax-variants.html


Developed by Leo Phan